Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive
iodine.
PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients
with locoregionally extensive or metastatic thyroid cancer.